Literature DB >> 6172379

Differentiation of mumps virus strains with monoclonal antibody to the HN glycoprotein.

A C Server, D C Merz, M N Waxham, J S Wolinsky.   

Abstract

A hybridoma cell line secreting antibody of the immunoglobulin G3 isotype with kappa light chains and with activity against the HN glycoprotein of the Kilham strain of mumps virus was established. The antibody exhibited structural homogeneity in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and had a microheterogeneous isoelectric spectrum characteristic of an antibody of monoclonal origin. The specificity of the monoclonal antibody, shown by immunoprecipitation performed with radiolabeled virus and infected cell lysates, was for the larger mumps virus glycoprotein. In functional assays the antibody inhibited the hemagglutinating and neuraminidase activities and neutralized the infectivity of the homologous Kilham strain of virus and clearly differentiated this strain from two heterologous strains, Enders and O'Take. The antibody was markedly less effective with the O'Take strain than with either the Kilham or Enders strain in inhibiting both hemagglutination and neuraminidase activity against the macromolecular substrate fetuin. The inhibition of the neuraminidase activity of the Kilham strain was independent of substrate size, the antibody inhibiting the hydrolysis of both fetuin and the trisaccharide neuraminlactose. By contrast, the antibody did not inhibit the hydrolysis of neuraminlactose by the two heterologous mumps strains. These results provide the first demonstration of antigenic differences between mumps virus strains and highlight the utility of monoclonal antibody in analyzing the structural basis underlying functional activities of the HN glycoproteins.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6172379      PMCID: PMC351013          DOI: 10.1128/iai.35.1.179-186.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  AN IMMUNOLOGICAL STUDY OF AVIAN, VIRAL AND BACTERIAL NEURAMINIDASE BASED ON SPECIFIC INHIBITION OF ENZYME BY ANTIBODY.

Authors:  G L ADA; P E LIND
Journal:  J Gen Microbiol       Date:  1963-08

2.  Hemagglutination behavior of mumps virus strains of different origin.

Authors:  V J CABASSO; H R COX
Journal:  Proc Soc Exp Biol Med       Date:  1955-03

3.  Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids.

Authors:  D AMINOFF
Journal:  Biochem J       Date:  1961-11       Impact factor: 3.857

4.  [Hemagglutinating capacity of nine strains of mumps virus towards erythrocytes of various species].

Authors:  F CHALLUT; Y CHARDONNET; G FAVIER; R SOHIER
Journal:  Ann Inst Pasteur (Paris)       Date:  1956-08

5.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

6.  Inhibition of the neuraminidase of paramyxoviruses by halide ions: a possible means of modulating the two activities of the HN protein.

Authors:  D C Merz; P Prehm; A Scheid; P W Choppin
Journal:  Virology       Date:  1981-07-15       Impact factor: 3.616

7.  Biochemical features of mumps virus neuraminidases and their relationship with pathogenicity.

Authors:  D C Merz; J S Wolinsky
Journal:  Virology       Date:  1981-10-15       Impact factor: 3.616

8.  Mutational changes of the protease susceptibility of glycoprotein F of Newcastle disease virus: effects on pathogenicity.

Authors:  W Garten; W Berk; Y Nagai; R Rott; H D Klenk
Journal:  J Gen Virol       Date:  1980-09       Impact factor: 3.891

9.  Characterization of immune complexes in progressive rubella panencephalitis.

Authors:  P K Coyle; J S Wolinsky
Journal:  Ann Neurol       Date:  1981-06       Impact factor: 10.422

10.  Some properties of mumps virus neuraminidase.

Authors:  H Klamm
Journal:  Acta Virol       Date:  1980-03       Impact factor: 1.162

View more
  11 in total

1.  Neutralizing activity of the antibodies against two kinds of envelope glycoproteins of Sendai virus.

Authors:  H Tozawa; H Komatsu; K Ohkata; T Nakajima; M Watanabe; Y Tanaka; M Arifuku
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

2.  Anti-idiotypic antibodies to rubella virus.

Authors:  A Nath; B Slagle; J S Wolinsky
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

3.  The effects of monoclonal antibodies against the hemagglutinin-neuraminidase and fusion protein on the release of Sendai virus from infected cells.

Authors:  C Orvell; K Kristensson
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

4.  Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis.

Authors:  J S Wolinsky; M N Waxham; A C Server
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

5.  Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays.

Authors:  Jeremy Mauldin; Kathryn Carbone; Henry Hsu; Robert Yolken; Steven Rubin
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

Review 6.  Monoclonal antibodies against microorganisms.

Authors:  R A Polin
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

7.  Cloning and nitrate induction of nitrate reductase mRNA.

Authors:  C L Cheng; J Dewdney; A Kleinhofs; H M Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

8.  Intracellular maturation of mumps virus hemagglutinin-neuraminidase glycoprotein: conformational changes detected with monoclonal antibodies.

Authors:  M N Waxham; D C Merz; J S Wolinsky
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

9.  Activation of the alternative complement pathway by mumps infected cells: relationship to viral neuraminidase activity.

Authors:  R L Hirsch; J S Wolinsky; J A Winkelstein
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

10.  Chapter 8 Paramyxoviruses.

Authors: 
Journal:  Perspect Med Virol       Date:  2008-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.